… untreated metastatic NSCLC with PD-L1 TPS ≥ 50% and no sensitizing EGFR or ALK
aberrations were randomly allocated 1:1 to ipilimumab 1 mg/kg or placebo every 6 weeks for up …

… -PD-(L)1 (innate or acquired resistance) and who then received either ipilimumab monotherapy
or ipilimumab plus anti-PD-1 (… of ipilimumab compared with ipilimumab plus anti-PD-1. …

… ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the
group that received ipilimumab and placebo (ipilimumab-… no patients in the ipilimumab-monotherapy …

… ipilimumab-matched placebo); or ipilimumab at a dose of 3 mg per kilogram every 3 weeks
for four doses (plus nivolumab-matched placebo… cell death ligand 1 (PD-L1) status. Treatment …

… (N=945) were randomized 1:1:1 to NIVO 1 mg/kg Q3W + IPI 3 … placebo, or IPI 3 mg/kg Q3W
for 4 doses + placebo, until progression or unacceptable toxicity. Pts were stratified by PD-L1 …

… 1:1 ratio to receive bone-directed RT followed by either ipilimumab intravenously at 10 mg/kg
or placebo … Nonprogressing patients could receive ipilimumab at 10 mg/kg or placebo as …

… ipilimumab-matching placebo during weeks 1–12); or nivolumab-matching placebo plus
ipilimumab-matching placebo … by nivolumab-matching placebo as maintenance therapy every 2 …

… (N = 945) were randomized 1:1:1 to NIVO 1 mg/kg Q2W + IPI … placebo, or IPI 3 mg/kg Q3W
for 4 doses + placebo, until progression or unacceptable toxicity. Pts were stratified by PD-L1 …

… ipilimumab combination therapy (95 patients) or ipilimumab and placebo (ipilimumab
monotherapy; 47 patients [figure 1]). … plus ipilimumab group and 37 in the ipilimumab plus placebo …

… mg/kg of intravenous nivolumab every 3 weeks plus 3 mg/kg of intravenous ipilimumab …
plus ipilimumab-matching placebo during weeks 1–12), or double-matching placebo group. The …